3//SEC Filing
PJSC Pharmsynthez 3
Accession 0001711454-17-000003
CIK 0001534525other
Filed
Oct 26, 8:00 PM ET
Accepted
Oct 27, 8:24 PM ET
Size
15.5 KB
Accession
0001711454-17-000003
Insider Transaction Report
Form 3
PJSC Pharmsynthez
10% Owner
Holdings
Warrants
From: 2016-03-31Exp: 2021-03-31→ Common Stock (353,540 underlying)- 821,567(indirect: By LLC)
Common Stock
- 970,000(indirect: By LLC)
Series A Preferred Stock
Warrants
Exercise: $4.95From: 2016-08-26Exp: 2021-08-26→ Common Stock (17,980 underlying)- 4,544,488
Common Stock
- 1,454,545
Series B Preferred Stock
Warrants
From: 2016-07-01Exp: 2021-07-01→ Common Stock (50,506 underlying)Warrants
Exercise: $4.95From: 2016-09-09Exp: 2021-09-09→ Common Stock (32,526 underlying)Class B Warrants
Exercise: $4.00From: 2016-11-07Exp: 2021-11-07→ Common Stock (1,454,545 underlying)Warrants
From: 2015-07-01Exp: 2020-07-01→ Common Stock (606,062 underlying)- (indirect: By LLC)
Warrants
Exercise: $25.41From: 2014-12-31Exp: 2019-12-30→ Common Stock (204,394 underlying)
Footnotes (3)
- [F1]Warrants are exercisable at the lesser of (i) $6.60 per share and (ii) 120% of the price per share of Xenetic Biosciences, Inc. common stock paid in its next occurring capital raise with a value of at least $7,000,000. Warrants were granted at six various dates in Q1 2016.
- [F2]The Reporting Person owns Class B Warrants exercisable into 1,454,545 shares of Common Stock. The exercise of such Class B Warrants is limited by the beneficial ownership limitation included in such Class B Warrants, which provides that such Class B Warrants may not be exercised if the holder thereof would own more than 4.99% of the outstanding Common Stock of the Issuer as after giving effect to such exercise. The amount of shares of Common Stock into which such Class B Warrants are exercisable was calculated for the purposes of this report without giving effect to any ownership limitation of the Reporting Person.
- [F3]The Reporting Person's wholly owned subsidiary, LLC SynBio, owns warrants exercisable into 204,394 shares of Common Stock. Such warrants are subject to performance vesting. The vesting milestones need to be achieved by December 31, 2017 (50%) and July 31, 2018 (50%). The amount of shares of Common Stock into which such warrants are exercisable was calculated for the purposes of this report without giving effect to any performance vesting limitations.
Documents
Issuer
Xenetic Biosciences, Inc.
CIK 0001534525
Entity typeother
IncorporatedRussian Federation
Related Parties
1- filerCIK 0001711454
Filing Metadata
- Form type
- 3
- Filed
- Oct 26, 8:00 PM ET
- Accepted
- Oct 27, 8:24 PM ET
- Size
- 15.5 KB